Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EndoTAG-1 in triple receptor negative metastatic breast cancer
2006-002221-23Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Oct 2006
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of EndoTAG-1 in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Medigene AG. Primary endpoint: 4-month progression-free survival rate. Started Oct 2006; status: completed.
02
Drugs
EndoTAG-1
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2006-002221-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002221-23.